

Inhibition of Mitotic Aurora Kinase A by Alisertib Induces Apoptosis and Autophagy of Human Gastric Cancer AGS and NCI-N78 Cells [Retraction]

Yuan C, Zhou Z, Yang Y, et al. *Drug Des Devel Ther.* 2015;9:487–508.

We, the Editors and Publisher of the journal *Drug Design, Development and Therapy*, have retracted the published article.

After publication, concerns were raised by a third party regarding the integrity of the data in Figure 5, Figure 7 and Figure 11 of the article. Further investigations conducted by the Journal and Publisher confirmed the following:

- Figure 5 includes duplicate image panels between samples representative of different experimental conditions;
- Unexpected similarities have been identified in the Western blot data shown in Figures 5a and 7a of the above article, and Figure 4a of the authors' published article, which represent different experimental conditions. Both articles were submitted contemporaneously:

Yuan C, Zhou Z, Yang Y, et al. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells. *Drug Des Devel Ther.* 2015;9:1293–1318. <https://doi.org/10.2147/DDDT.S74964>

When approached for an explanation, the authors checked their data and confirmed there are fundamental errors present. Therefore, they have agreed to the retraction of this article. The authors apologize for this oversight.

We have been informed in our decision-making by our editorial policies and the COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as 'Retracted'.

Drug Design, Development and Therapy

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>

Dovepress
Taylor & Francis Group

<https://doi.org/10.2147/DDDT.S571572>

Received: 1 October 2025
Accepted: 1 October 2025
Published: 3 October 2025

Drug Design, Development and Therapy 2025:19 8997



© 2025 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <https://www.dovepress.com/terms.php> and incorporate the Creative Commons Attribution – Non Commercial (unported, v4.0) License (<http://creativecommons.org/licenses/by-nc/4.0/>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<https://www.dovepress.com/terms.php>).

8997